首页> 外文OA文献 >Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials

【2h】

Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials

机译：血肿瘤突变负担作为多西紫杉醇治疗的非小细胞肺癌患者临床益处的预测因素：橡木和白杨的二次分析随机临床试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
W. Nie; J. Qian; B.-H. Han;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 吉非替尼治疗局部晚期或转移性非小细胞肺癌患者疗效及生存的临床预测因素——两项Ⅱ期临床研究的综合分析 [J] . 赵媛媛, 张阳, 赵洪云, 癌症（英文版） . 2009,第006期
2. The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy [J] . Yukie Omori1, Sotaro Enatsu1, Alan J.M. Brnabic, 肺癌 . 2019,第7期

机译：与多西紫杉醇的两次随机临床试验的后HOC分析，多西紫杉醇相关的FERESOPENIA对患者报告的症状和日本人的生活质量和生活质量的相关性。在铂基化疗的进展后，不含抗血管生成剂在先进的非小细胞肺癌中
3. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy [J] . Perol Maurice, Ciuleanu Tudor-Eliade, Arrieta Oscar, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期

机译：生活质量来自雷莫昔单抗加多西他赛与安慰剂加多西他赛在铂类化疗后进展的晚期/转移性非小细胞肺癌患者的3期REVEL随机临床试验中的结果
4. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. [J] . Di-Leo A, Tanner M, Desmedt C, Annals of oncology: official journal of the European Society for Medical Oncology . 2007,第6期

机译：在III期临床试验的背景下，p-53基因突变可作为随机标记阿霉素或多西他赛治疗的晚期乳腺癌患者群体的预测标记。
5. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
6. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
7. Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies [O] . Yu-tong Chen, Sharvesh Raj Seeruttun, Xiang-yuan Wu, 2019

机译：最大体态等位基因频率与血基肿瘤突变负担的结合预测atezolizumab在先进的非小细胞肺癌中的功效：随机杨树和橡树研究的汇总分析
8. Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies [O] . Yu-tong Chen, Sharvesh Raj Seeruttun, Xiang-yuan Wu, 2019

机译：最大体态等位基因频率与血基肿瘤突变负担的结合预测atezolizumab在先进的非小细胞肺癌中的功效：随机杨树和橡树研究的汇总分析

Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials

著录项

引文网络

相似文献

相关主题

期刊订阅